<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02054338</url>
  </required_header>
  <id_info>
    <org_study_id>L00070 IN 303 B0</org_study_id>
    <secondary_id>2006-001139-23</secondary_id>
    <nct_id>NCT02054338</nct_id>
  </id_info>
  <brief_title>A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer</brief_title>
  <acronym>VICTORIA</acronym>
  <official_title>Phase III Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer After Prior Anthracycline-based Adjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of vinflunine and gemcitabine in advanced breast cancer in comparison to
      paclitaxel and gemcitabine is based on the following points: the significant antitumour
      activity of vinflunine in metastatic breast cancer (MBC) as single agent after
      anthracycline-taxane exposure and recent phase I study results of the vinflunine plus
      gemcitabine is at least additive and both drugs have a distinct mechanism of action; since
      taxanes have been approved in the adjuvant setting and are widely used in the treatment of
      early breast cancer it is worthwhile to assess new combination chemotherapy regimens as first
      line therapy for metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, multicentre, open-label phase III study comparing antitumour efficacy
      of vinflunine plus gemcitabine versus paclitaxel plus gemcitabine, as first line treatment
      for patients with unresectable, locally recurrent or metastatic breast cancer after prior
      anthracycline-based adjuvant chemotherapy.

      Patients with metastatic breast cancer are incurable using conventional therapy with
      antitumoural hormonal drugs or cytostatic agents. The median survival from diagnosis of
      metastatic disease to death is reported to be approximately 3 years. While newer
      chemotherapeutic agents have been able to achieve tumour shrinkage, no significant increases
      in overall survival have been demonstrated so far. One reason for this result may be that
      breast cancer has a longer disease time span than NSCLC, allowing for administration of
      multiple therapies with different modalities. These therapies confound overall survival
      regardless of whether the treatment is a first-line or a subsequent treatment. The
      combination of gemcitabine plus paclitaxel has demonstrated improvement in overall survival
      over paclitaxel alone as first line therapy in patients with locally recurrent or metastatic
      breast cancer, however, this study compared single agent versus combination chemotherapy.

      Using overall survival as a primary endpoint in a trial Using overall survival as a primary
      endpoint in a trial comparing 2 different cytostatic combinations in the treatment of
      metastatic breast cancer requires a large phase III study to detect a clinically significant
      difference. The advantages with such an endpoint are that it is technically easy to monitor
      and it is not dependent on monitoring tumour status. However, since patients with breast
      cancer typically receive 3 or more lines of chemotherapy, it becomes difficult to assess the
      impact of a first-line therapy on overall survival (as proposed herein) due to the potential
      for confounding effects from later treatments. A more specific instrument -if closely
      monitored- is progression-free survival. This endpoint reflects the impact of a specific
      treatment modality on the disease at a given time period and is probably confounded neither
      by prior treatments nor by subsequent therapies. Progression-free survival also represents an
      important clinical achievement for patients with metastatic breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was stopped before progressive disease or death of alive subjects.
  </why_stopped>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>PFS was calculated from the registration date until the date of progression or death due to any cause if no progression was recorded first (median duration of follow-up: 14.1 months)</time_frame>
    <description>The primary efficacy parameter was Progression-free survival (PFS) analysed in the Intent-to-treat (ITT) population. PFS was defined as the time elapsed from randomisation date until the date of progression or death due to any cause (whichever came first).Tumor response was evaluated using the RECIST version 1.0 every 6 weeks until progression was recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>OS was evaluated from the date of registration to the date of death due to any cause (median duration of follow-up: 14.1 months)</time_frame>
    <description>The secondary efficacy parameter was Overall Survival (OS) analysed in the Intent-to-treat (ITT) population. OS was defined as the time elapsed from the date of randomisation up to death or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate &amp; Disease Control Rate</measure>
    <time_frame>ORR and DCR were calculated from the date of randomisation of first patient until the database cut-off (30 June 2011), assessed up to 5 years</time_frame>
    <description>Disease control rate (DCR) is defined as the sum of Complete Response (CR) and Partial Response (PR) and Stable Disease (SD) ≥ 6 months rate. Objective response rate (ORR) is defined as the sum of Complete Response (CR) and Partial Response (PR) rate (using the best confirmed response recorded from the date of randomisation to the end of treatment). DCR and ORR, assessed by Independent Review Committee using RECIST 1.0, were calculated in the ITT population.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1004</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>vinflunine plus gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vinflunine 320 mg/m² D1 plus gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paclitaxel plus gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>paclitaxel 175 mg/m² D1 followed by Gemcitabine 1250 mg/m² D1 and D8 every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinflunine+Gemcitabine</intervention_name>
    <description>Vinflunine 320 mg/m² IV on day 1 and.Gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks</description>
    <arm_group_label>vinflunine plus gemcitabine</arm_group_label>
    <other_name>L0070 IN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel+Gemcitabine</intervention_name>
    <description>paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1</description>
    <arm_group_label>paclitaxel plus gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female patients

          -  18 years or older but less than 75 years old

          -  histologically/cytologically confirmed breast cancer

          -  documented locally recurrent or metastatic breast cancer

          -  HER-2 negative or unknown

          -  prior neo- and/or adjuvant anthracycline-based chemotherapy

          -  measurable or non-measurable disease according to Response Evaluation Criteria In
             Solid Tumors (RECIST) 1.0

          -  adequate haematological, hepatic and renal functions

          -  ECG without any clinically relevant abnormality

        Exclusion Criteria:

          -  known or clinical evidence of brain metastases or leptomeningeal involvement

          -  history of second primary malignancy

          -  patients having as sole tumour lesion: malignant effusion, lymphangitis, cystic
             lesion, bone lesion, and any other lesion not assessed by imaging techniques or colour
             photography

          -  pre-existing motor/sensory grade &gt; 1 peripheral neuropathy

          -  prior therapy with vinca alkaloids and/or gemcitabine

          -  history of severe hypersensitivity to vinca alkaloids and/or gemcitabine or
             contraindication to any of these drugs

          -  pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Keddad, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Employed Pierre Fabre Medicament</affiliation>
  </overall_official>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 31, 2014</study_first_submitted>
  <study_first_submitted_qc>February 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <results_first_submitted>May 29, 2019</results_first_submitted>
  <results_first_submitted_qc>August 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2019</results_first_posted>
  <last_update_submitted>August 9, 2019</last_update_submitted>
  <last_update_submitted_qc>August 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vinflunine Plus Gemcitabine</title>
          <description>vinflunine 320 mg/m² D1 plus gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks
Vinflunine
vinflunine plus gemcitabine: 320 mg/m² IV on day 1 plus gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks</description>
        </group>
        <group group_id="P2">
          <title>Paclitaxel Plus Gemcitabine</title>
          <description>paclitaxel 175 mg/m² D1 followed by Gemcitabine 1250 mg/m² D1 and D8 every 3 weeks
paclitaxel plus gemcitabine: paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="503"/>
                <participants group_id="P2" count="501"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="503"/>
                <participants group_id="P2" count="501"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vinflunine Plus Gemcitabine</title>
          <description>vinflunine 320 mg/m² D1 plus gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks
Vinflunine
vinflunine plus gemcitabine: 320 mg/m² IV on day 1 plus gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks</description>
        </group>
        <group group_id="B2">
          <title>Paclitaxel Plus Gemcitabine</title>
          <description>paclitaxel 175 mg/m² D1 followed by Gemcitabine 1250 mg/m² D1 and D8 every 3 weeks
paclitaxel plus gemcitabine: paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="503"/>
            <count group_id="B2" value="501"/>
            <count group_id="B3" value="1004"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="428"/>
                    <measurement group_id="B2" value="438"/>
                    <measurement group_id="B3" value="866"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>The upper limit of full rage reported is higher than the one in the Eligibility Section of the Protocol. A total of 11 subjects (4 in the Vinflunine Plus Gemcitabine arm and 7 in the Paclitaxel Plus Gemcitabine arm) presented minor deviation at study entry.</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.2" lower_limit="24.1" upper_limit="77.7"/>
                    <measurement group_id="B2" value="54.4" lower_limit="21.5" upper_limit="79.0"/>
                    <measurement group_id="B3" value="53.6" lower_limit="21.5" upper_limit="79.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="503"/>
                    <measurement group_id="B2" value="501"/>
                    <measurement group_id="B3" value="1004"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>The primary efficacy parameter was Progression-free survival (PFS) analysed in the Intent-to-treat (ITT) population. PFS was defined as the time elapsed from randomisation date until the date of progression or death due to any cause (whichever came first).Tumor response was evaluated using the RECIST version 1.0 every 6 weeks until progression was recorded.</description>
        <time_frame>PFS was calculated from the registration date until the date of progression or death due to any cause if no progression was recorded first (median duration of follow-up: 14.1 months)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Vinflunine Plus Gemcitabine</title>
            <description>vinflunine 320 mg/m² D1 plus gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks
Vinflunine
vinflunine plus gemcitabine: 320 mg/m² IV on day 1 plus gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel Plus Gemcitabine</title>
            <description>paclitaxel 175 mg/m² D1 followed by Gemcitabine 1250 mg/m² D1 and D8 every 3 weeks
paclitaxel plus gemcitabine: paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>The primary efficacy parameter was Progression-free survival (PFS) analysed in the Intent-to-treat (ITT) population. PFS was defined as the time elapsed from randomisation date until the date of progression or death due to any cause (whichever came first).Tumor response was evaluated using the RECIST version 1.0 every 6 weeks until progression was recorded.</description>
          <population>ITT population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="7.2" upper_limit="8.9"/>
                    <measurement group_id="O2" value="8.4" lower_limit="7.6" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier curves and life tables by treatment arm to describe time-dependent parameters. Stratified Cox proportional model was used to compare the 2 treatment arms. A stratified Cox proportional hazards model and logistic regression were applied to the progression-free survival and to the tumour response, respectively.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The secondary efficacy parameter was Overall Survival (OS) analysed in the Intent-to-treat (ITT) population. OS was defined as the time elapsed from the date of randomisation up to death or last follow-up.</description>
        <time_frame>OS was evaluated from the date of registration to the date of death due to any cause (median duration of follow-up: 14.1 months)</time_frame>
        <population>ITT population - Cut-off date: 30 June 2011</population>
        <group_list>
          <group group_id="O1">
            <title>Vinflunine Plus Gemcitabine</title>
            <description>vinflunine 320 mg/m² D1 plus gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks
Vinflunine
vinflunine plus gemcitabine: 320 mg/m² IV on day 1 plus gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel Plus Gemcitabine</title>
            <description>paclitaxel 175 mg/m² D1 followed by Gemcitabine 1250 mg/m² D1 and D8 every 3 weeks
paclitaxel plus gemcitabine: paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The secondary efficacy parameter was Overall Survival (OS) analysed in the Intent-to-treat (ITT) population. OS was defined as the time elapsed from the date of randomisation up to death or last follow-up.</description>
          <population>ITT population - Cut-off date: 30 June 2011</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" lower_limit="16.9" upper_limit="22.6"/>
                    <measurement group_id="O2" value="19.1" lower_limit="17.8" upper_limit="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate &amp; Disease Control Rate</title>
        <description>Disease control rate (DCR) is defined as the sum of Complete Response (CR) and Partial Response (PR) and Stable Disease (SD) ≥ 6 months rate. Objective response rate (ORR) is defined as the sum of Complete Response (CR) and Partial Response (PR) rate (using the best confirmed response recorded from the date of randomisation to the end of treatment). DCR and ORR, assessed by Independent Review Committee using RECIST 1.0, were calculated in the ITT population.</description>
        <time_frame>ORR and DCR were calculated from the date of randomisation of first patient until the database cut-off (30 June 2011), assessed up to 5 years</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Vinflunine Plus Gemcitabine</title>
            <description>vinflunine 320 mg/m² D1 plus gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks
Vinflunine
vinflunine plus gemcitabine: 320 mg/m² IV on day 1 plus gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel Plus Gemcitabine</title>
            <description>paclitaxel 175 mg/m² D1 followed by Gemcitabine 1250 mg/m² D1 and D8 every 3 weeks
paclitaxel plus gemcitabine: paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate &amp; Disease Control Rate</title>
          <description>Disease control rate (DCR) is defined as the sum of Complete Response (CR) and Partial Response (PR) and Stable Disease (SD) ≥ 6 months rate. Objective response rate (ORR) is defined as the sum of Complete Response (CR) and Partial Response (PR) rate (using the best confirmed response recorded from the date of randomisation to the end of treatment). DCR and ORR, assessed by Independent Review Committee using RECIST 1.0, were calculated in the ITT population.</description>
          <population>ITT</population>
          <units>percentage of patients</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Response Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="8.7" upper_limit="14.4"/>
                    <measurement group_id="O2" value="14.6" lower_limit="11.6" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Control Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" lower_limit="35.5" upper_limit="44.2"/>
                    <measurement group_id="O2" value="44.9" lower_limit="40.5" upper_limit="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>11.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.7</ci_lower_limit>
            <ci_upper_limit>14.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Each subject was assessed for occurrence of Adverse Events throughout the study period (treatment period and follow-up period), up to 8 years.</time_frame>
      <desc>Safety data are presented for the global safety population which include the safety data of the 13 patients ongoing treatment (up to the premature termination date 18 February 2015). Safety population is defined as all treated patients analysed in the treatment arm they received (n=495 subjects in the Vinflunine Plus Gemcitabine arm and n=496 in the Paclitaxel Plus Gemcitabine arm)</desc>
      <group_list>
        <group group_id="E1">
          <title>Vinflunine Plus Gemcitabine</title>
          <description>vinflunine 320 mg/m² D1 plus gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks
Vinflunine
vinflunine plus gemcitabine: 320 mg/m² IV on day 1 plus gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks</description>
        </group>
        <group group_id="E2">
          <title>Paclitaxel Plus Gemcitabine</title>
          <description>paclitaxel 175 mg/m² D1 followed by Gemcitabine 1250 mg/m² D1 and D8 every 3 weeks
paclitaxel plus gemcitabine: paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="406" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="394" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Thrombocythamia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Ventricular dysfunction</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Anal inflammation</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Generalized oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Catheter-related infection</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Infection NOS</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Orophrayngeal candidiasis</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Abscess soft tissue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Genitourinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Nail bed infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Viral pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT increased</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hyperkaelemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Metabolic alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour pain</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Reversible posterior leukoencephalopathy syndrome</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Depressed level of consciouness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Alveolitis</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Orthopnea</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pulmonary ooedema</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Chronic pulmonary obstructive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus management</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Malignant tumour excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Superior vena cava occlusion</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Deep venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypovolemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Lymphooedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="494" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="494" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="295" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="249" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="239" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="266" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="220" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="216" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="314" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="286" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="226" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="202" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="317" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <description>Drug related</description>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>None reported</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Karim Keddad</name_or_title>
      <organization>Institut de Recherche Pierre Fabre</organization>
      <phone>+33 5 34 50 61 69</phone>
      <email>karim.keddad@pierre-fabre.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

